DK4419526T3 - Heterocykliske forbindelser til anvendelse i behandlingen af cancer - Google Patents

Heterocykliske forbindelser til anvendelse i behandlingen af cancer Download PDF

Info

Publication number
DK4419526T3
DK4419526T3 DK22797829.3T DK22797829T DK4419526T3 DK 4419526 T3 DK4419526 T3 DK 4419526T3 DK 22797829 T DK22797829 T DK 22797829T DK 4419526 T3 DK4419526 T3 DK 4419526T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
DK22797829.3T
Other languages
Danish (da)
English (en)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam Mann
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Application granted granted Critical
Publication of DK4419526T3 publication Critical patent/DK4419526T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK22797829.3T 2021-10-21 2022-10-21 Heterocykliske forbindelser til anvendelse i behandlingen af cancer DK4419526T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
DK4419526T3 true DK4419526T3 (da) 2025-02-17

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22797829.3T DK4419526T3 (da) 2021-10-21 2022-10-21 Heterocykliske forbindelser til anvendelse i behandlingen af cancer

Country Status (24)

Country Link
US (2) US20240425511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4419527A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024539132A (cg-RX-API-DMAC7.html)
KR (1) KR20240099274A (cg-RX-API-DMAC7.html)
CN (2) CN119053600A (cg-RX-API-DMAC7.html)
AR (1) AR127431A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022374050A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233255A1 (cg-RX-API-DMAC7.html)
DK (1) DK4419526T3 (cg-RX-API-DMAC7.html)
ES (1) ES3008687T3 (cg-RX-API-DMAC7.html)
FI (1) FI4419526T3 (cg-RX-API-DMAC7.html)
GB (1) GB202115156D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250334T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070568T2 (cg-RX-API-DMAC7.html)
IL (1) IL311922A (cg-RX-API-DMAC7.html)
LT (1) LT4419526T (cg-RX-API-DMAC7.html)
MX (1) MX2024004874A (cg-RX-API-DMAC7.html)
PL (1) PL4419526T3 (cg-RX-API-DMAC7.html)
PT (1) PT4419526T (cg-RX-API-DMAC7.html)
RS (1) RS66620B1 (cg-RX-API-DMAC7.html)
SI (1) SI4419526T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500123T1 (cg-RX-API-DMAC7.html)
TW (1) TW202334150A (cg-RX-API-DMAC7.html)
WO (2) WO2023067355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10760081B2 (en) 2015-10-07 2020-09-01 New York University Compositions and methods for enhancing CRISPR activity by POLQ inhibition
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
GB202115156D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115158D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds
GB202115150D0 (en) * 2021-10-21 2021-12-08 Artios Pharma Ltd Novel compounds

Also Published As

Publication number Publication date
MX2024004874A (es) 2024-05-06
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
SMT202500123T1 (it) 2025-05-12
EP4419526A1 (en) 2024-08-28
LT4419526T (lt) 2025-03-25
CN119053600A (zh) 2024-11-29
TW202334150A (zh) 2023-09-01
RS66620B1 (sr) 2025-04-30
AU2022374050A1 (en) 2024-05-02
JP2024542949A (ja) 2024-11-19
WO2023067356A1 (en) 2023-04-27
PL4419526T3 (pl) 2025-04-22
US20240425511A1 (en) 2024-12-26
EP4419526B1 (en) 2024-12-25
EP4419527A1 (en) 2024-08-28
HUE070568T2 (hu) 2025-06-28
WO2023067355A1 (en) 2023-04-27
KR20240099274A (ko) 2024-06-28
ES3008687T3 (en) 2025-03-24
CA3233255A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
PT4419526T (pt) 2025-02-03
US20260124214A1 (en) 2026-05-07
FI4419526T3 (fi) 2025-02-13
AR127431A1 (es) 2024-01-24
HRP20250334T1 (hr) 2025-06-06
GB202115156D0 (en) 2021-12-08
IL311922A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
DK4010329T3 (da) Deutererede forbindelser til anvendelse ved behandling af cancer
DK3902803T3 (da) Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft
DK4096717T3 (da) Behandling af cancer
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK4303583T3 (da) Csf1r-inhibitorer til anvendelse til behandling af tenosynoviale kæmpecelletumorer
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
EP4010080C0 (en) HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
DK3496739T3 (da) Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
DK4339615T3 (da) Anti-PD-1-antistof til anvendelse i behandlingen af kræft
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3601296T3 (da) 2-oxo-thiazolderivater som a2a-inhibitorer og forbindelser til anvendelse ved behandling af cancere
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
DK4225297T3 (da) Kombinationsbehandling til behandling af cancer
DK4340842T3 (da) Sotorasib til anvendelse ved behandling af kræft
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3416945T3 (da) 6-aryl-4-(morpholin-4-yl)-1h-pyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
HRP20260406T1 (hr) Lumateperon za primjenu u liječenju shizofrenije
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer